Huemer, Florian
Hecht, Stefan
Scharinger, Bernhard
Schlintl, Verena
Rinnerthaler, Gabriel
Schlick, Konstantin
Heregger, Ronald
Melchardt, Thomas
Wimmer, Angela
Mühlbacher, Iris
Koch, Oliver Owen
Neureiter, Daniel
Klieser, Eckhard
Seyedinia, Sara
Beheshti, Mohsen
Greil, Richard
Weiss, Lukas
Funding for this research was provided by:
Paracelsus Medical University
Article History
Received: 3 April 2022
Accepted: 27 May 2022
First Online: 21 July 2022
Declarations
:
: Florian Huemer received honoraria from Eli Lilly, Pierre Fabre, Amgen, Servier, Daiichi Sankyo and BMS; travel support from Servier, BMS, Roche, Merck, Pharmamar, Pfizer and Pierre Fabre. Konstantin Schlick received honoraria from Servier, Amgen and AstraZeneca; payment for expert testimony from Servier and Amgen; travel support from Servier and Pfizer. Gabriel Rinnerthaler received honoraria from Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Pierre Fabre, Eli Lilly, MSD, Novartis, Amgen and Merck; travel support from Roche and Pfizer; and reports participation at advisory boards of Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Pierre Fabre, Eli Lilly, MSD, Novartis, Amgen and Merck. Richard Greil received consulting fees from Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer; honoraria from Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi, Pfizer; travel support from Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer; participated at advisory boards of Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer; and reports other financial or non-financial interests for Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer. Lukas Weiss received grants from the Paracelsus Medical University Salzburg and the Krebshilfe Salzburg; consulting fees from Merck; travel support from Pfizer, IPSEN and AstraZeneca; and has the leadership of the Colorectal Branch of the Austrian Breast and Colorectal Cancer study group. Stefan Hecht, Bernhard Scharinger, Angela Wimmer, Iris Mühlbacher, Daniel Neureiter, Eckhard Klieser, Oliver Koch, Ronald Heregger, Verena Schlintl, Thomas Melchardt, Mohsen Beheshti and Sara Seyedinia declare no conflicts of interest.
: Florian Huemer received honoraria from Eli Lilly, Pierre Fabre, Amgen, Servier, Daiichi Sankyo and BMS; travel support from Servier, BMS, Roche, Merck, Pharmamar, Pfizer and Pierre Fabre. Konstantin Schlick received honoraria from Servier, Amgen and AstraZeneca; payment for expert testimony from Servier and Amgen; travel support from Servier and Pfizer. Gabriel Rinnerthaler received honoraria from Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Pierre Fabre, Eli Lilly, MSD, Novartis, Amgen and Merck; travel support from Roche and Pfizer; and reports participation at advisory boards of Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Pierre Fabre, Eli Lilly, MSD, Novartis, Amgen and Merck. Richard Greil received consulting fees from Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer; honoraria from Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi, Pfizer; travel support from Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer; participated at advisory boards of Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer; and reports other financial or non-financial interests for Celgene, Novartis, Roche, BMS, Takeda, Abbvie, AstraZeneca, Janssen, MSD, Merck, Gilead, Daiichi Sankyo, Sanofi and Pfizer. Lukas Weiss received grants from the Paracelsus Medical University Salzburg and the Krebshilfe Salzburg; consulting fees from Merck; travel support from Pfizer, IPSEN and AstraZeneca; and has the leadership of the Colorectal Branch of the Austrian Breast and Colorectal Cancer study group. Stefan Hecht, Bernhard Scharinger, Angela Wimmer, Iris Mühlbacher, Daniel Neureiter, Eckhard Klieser, Oliver Koch, Ronald Heregger, Verena Schlintl, Thomas Melchardt, Mohsen Beheshti and Sara Seyedinia declare no conflicts of interest.
: This retrospective analysis was approved by the Ethics Committee of the provincial government of Salzburg, Austria, on 04 September 2018 (protocol number: 415-EP/73/789–2018).
: Not applicable.
: Due to the retrospective character of this analysis and the approval by the Ethics Committee of the provincial government of Salzburg informed consent was not required.